Clinical Trial Update: Evaluating Efficacy and Safety of Etanercept 50 mg Twice Weekly (BIW) in Rheumatoid Arthritis (RA) Subjects Who Are Sub-Optimal Responders to Etanercept 50 mg Once Weekly (QW) [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating the efficacy and safety of etanercept 50 mg twice weekly in rheumatoid arthritis patients who had sub-optimal response to etan…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• ENBREL (etanercept)

Snippet

Sponsor: Amgen | Conditions: Rheumatoid Arthritis | Phase 4 | Status: COMPLETED